History

1958

Company founded.

1988

King-phar plant founded.

1993

Advanced technology for manufacturing lyophilized powder imported from Germany, Spain and France.

1995

Genetic engineering plant founded with a total surface area of 2,500 m².

1999

G-CSF was firstly launched in China. Qilu became one of the biggest supplier of antibiotic APIs in the world.

2002

First inspection and approval by USFDA.

2003

Changed from a State-owned to a private company.

2006

Launched Permetrexed which extended the oncology portfolio. High-tech zone and Hainan manufacturing site founded.

2008

Approved by MHRA (Medicine and Healthcare products Regulatory Administration of UK) for sterile API and by TGA (Therapeutic Goods Administration of Australia) for powder for injection and small volume parenteral solutions.

2009

Qilu Drug Research Institute established and two additional sites founded in Neimenggu and Linyi.

2010

EDQM (European Directorate for the Quality of Medicines) approved 5 sterile products of Qilu Antibiotics.

2011

Approved by FDA (US Food and Drug Administration) for sterile API and by Germany Authority for powder for injection.

2013

Approved by FDA (US Food and Drug Administration) for powder for injection and Solid Oral Dosage.

2014

Approved by AEMPS (Spanish Agency for Medicines and Health Products) for lyophilized powder for injection.

2015

Approved by MHRA (Medicine and Healthcare products Regulatory Administration United Kindom) for powder for injection.